ANDA 204043, held by Rising. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 204043 (Mycophenolate Mofetil Hydrochloride), held by Rising, was first approved by FDA on Feb 28, 2017, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 28, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Rx |
| Jul 29, 2026 | Supplement 18REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 16REMS | Approved | None posted |
| Jul 3, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 3, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jul 3, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Aug 11, 2021 | Supplement 11REMS | Approved | None posted |
| Apr 21, 2021 | Supplement 9REMS | Approved | None posted |
| Jan 15, 2021 | Supplement 8REMS | Approved | None posted |
| Nov 27, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 27, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 27, 2019 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 28, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters